What is the prevalence of stimulant use and the risk of dependence in adults with attention-deficit/hyperactivity disorder (ADHD)?

Prevalence and Risk of Dependence of Stimulants for Adult ADHD

Stimulant medications for adult ADHD are associated with reduced—not increased—risk of substance abuse and dependence, with evidence showing 31-35% lower rates of substance-related problems during treatment periods. 1

Prevalence of Stimulant Use in Adults with ADHD

Among adults diagnosed with ADHD, approximately 32.7% use stimulant medications 2. However, this rate is notably lower among those with comorbid substance use disorders, where clinicians appear hesitant to prescribe stimulants despite emerging evidence supporting their safety 3, 4.

The prevalence of ADHD diagnoses among patients with opioid use disorder has increased dramatically from 4.6% in 2007 to 15.1% in 2017, though only 10.5% of patients receiving medications for opioid use disorder received stimulant prescriptions during this period 4.

Risk of Dependence: The Evidence Contradicts Common Fears

Key Finding: Protective Effect Against Substance Abuse

The most robust recent evidence demonstrates that stimulant treatment is protective against substance abuse rather than causative:

• Concurrent protection: Male patients show 35% lower odds of substance-related events during months receiving medication (OR=0.65), while female patients show 31% lower odds (OR=0.69) 1

• Long-term protection: Male patients maintain 19% lower odds of substance-related events 2 years after medication periods (OR=0.81), with female patients showing 14% lower odds (OR=0.86) 1

• Dose-response relationship: Longer duration of medication correlates with lower rates of substance abuse, with a 31% reduction in substance abuse rates even after controlling for multiple covariates (HR=0.69) 5

• Mortality benefit: Overall ADHD treatment is associated with 30% lower risk of mortality (aHR=0.70) 3

Clinical Outcomes in Comorbid ADHD and Substance Use Disorder

Among adolescents and young adults with both ADHD and substance use disorder, ADHD treatment (including stimulants) is associated with:

• Fewer hospitalizations and emergency department visits
• Reduced suicidal ideation and attempts (RR range: 0.74-0.82)
• Better engagement with psychiatric services (RR=1.23)
• Fewer accidental overdoses when comparing stimulants to nonstimulants (RR range: 0.63-0.79) 3

Critical Caveat: The Comorbid Substance Abuse Concern

The primary guideline caution remains valid: prescribing stimulants to adults with active, untreated substance abuse disorder requires heightened vigilance 6. However, this is not an absolute contraindication. The 2002 AACAP guidelines specifically note that "patients who have histories of using or abusing other substances, such as cigarettes, alcohol, opiates, benzodiazepines, or sedatives...may have stimulants given to treat their ADHD. Even a history of abuse of stimulants may not represent an absolute contraindication" 6.

Risk Factors for Long-term Concurrent Stimulant-Opioid Use

Among adults with ADHD, 5.4% become long-term concurrent users of stimulants and opioids 2. Risk factors include:

• Older age (prevalence increases progressively from 20s through 50s)
• Non-Hispanic white ethnicity
• Southern US residence
• Comorbid diagnoses: substance abuse disorder, depression, anxiety, chronic pain, COPD, cardiovascular disease 2

Long-term opioid use is actually more common among ADHD patients who use stimulants (16.5%) compared to those who don't (13.0%), though this likely reflects confounding by indication rather than causation 2.

Practical Clinical Algorithm

For adults with ADHD without active substance use disorder:

• Prescribe stimulants as first-line treatment (methylphenidate 5-20 mg tid or dextroamphetamine 5 mg tid to 20 mg bid) 6
• Monitor for diversion and misuse but recognize the protective effect against future substance problems

For adults with ADHD and comorbid substance use disorder:

• Do not automatically avoid stimulants—the evidence suggests benefit, not harm 1, 3
• Consider longer-acting formulations resistant to diversion (e.g., Concerta) 6
• Ensure close monitoring with more frequent follow-up
• Coordinate care with addiction treatment providers
• Consider nonstimulants (atomoxetine, viloxazine ER, bupropion) if concerns about diversion are paramount, though stimulants show superior outcomes 3, 7

For adults with active, untreated substance abuse:

• Stabilize substance use disorder first when possible
• If ADHD symptoms are severely impairing, stimulants can still be considered with intensive monitoring 6
• Obtain urine drug screens and involve collateral informants 6

Common Pitfalls to Avoid

1. Withholding effective treatment due to outdated fears: The "black box" warning about drug dependence in package inserts is not supported by contemporary evidence showing protective effects 6, 5, 1

2. Assuming all substance use history is equal: History of non-stimulant substance use (alcohol, opiates, benzodiazepines) should not preclude stimulant treatment 6

3. Ignoring the mortality benefit: Untreated ADHD with comorbid substance use disorder carries significant mortality risk that stimulant treatment reduces 3

4. Relying solely on patient self-report: Adults with ADHD are unreliable reporters of their own behaviors; obtain collateral information from family members or significant others 6